Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons

    September 2025 in “ Dermatology and Therapy ”
    Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, M. La Plaça, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi, Michela Starace
    Image
    Studysummary This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in treating type 2 diabetes and obesity, with additional benefits for dermatologic conditions like psoriasis and hidradenitis suppurativa due to their anti-inflammatory and immunomodulatory effects. However, they can cause cutaneous adverse reactions and pose challenges in aesthetic and reconstructive surgery, such as facial volume depletion and impaired wound healing due to rapid weight loss. Additionally, delayed gastric emptying from GLP-1 RAs necessitates careful perioperative management to mitigate risks like pulmonary aspiration. This review evaluates the benefits and risks of GLP-1 RAs for dermatologists and plastic surgeons.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results